Fulgent Genetics Inc (FLGT)vsWaters Corporation (WAT)
FLGT
Fulgent Genetics Inc
$19.64
+0.05%
HEALTHCARE · Cap: $558.64M
WAT
Waters Corporation
$379.48
-1.15%
HEALTHCARE · Cap: $35.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 1077% more annual revenue ($3.77B vs $320.35M). WAT leads profitability with a 11.9% profit margin vs -23.0%. FLGT appears more attractively valued with a PEG of 1.32. WAT earns a higher WallStSmart Score of 50/100 (C-).
FLGT
Hold40
out of 100
Grade: D
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.9%
Fair Value
$49.90
Current Price
$19.64
$30.26 discount
Margin of Safety
-81.9%
Fair Value
$180.97
Current Price
$379.48
$198.51 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.0% — below average capital efficiency
Revenue declined 3.2%
Earnings declined 98.6%
Expensive relative to growth rate
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FLGT
The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, Revenue Growth.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Operating Margin. A P/E of 46.9x leaves little room for execution misses.
Key Dynamics to Monitor
FLGT profiles as a turnaround stock while WAT is a growth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
FLGT generates stronger free cash flow (2M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 40/100) and 91.4% revenue growth. FLGT offers better value entry with a 53.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?